Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Steps On US FDA Hiring: Lobby For Strong Long-Term Plan After Freeze Is Lifted

Executive Summary

After OMB clarifying memo suggests freeze applies to user fee-supported staff, it could be up to FDA and stakeholders to convince the administration to spare the agency.

You may also be interested in...



Obamacare Repeal May Be Delaying User Fee Bill, Rep. DeGette Says

House Energy and Commerce Committee Democrat says few in-depth member talks about the user fee bill have taken place because of focus on ACA repeal and replacement.

US FDA May Find Relief From Trump's Hiring Freeze

Updated guidance indicates food and drug activities fall within public safety exemption, but interpretation of language remains unclear.

Trump Promises Changes To 'A Lot Of Rules' At US FDA

In meeting with PhRMA, president says FDA approval must be faster and that a commissioner pick is coming.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel